Brokers Set Expectations for CRSP FY2026 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Brookline Capital Markets increased their FY2026 earnings per share estimates for shares of CRISPR Therapeutics in a note issued to investors on Monday, November 2nd. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn ($4.74) per share for the year, up from their prior estimate of ($5.63). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($4.44) per share. Brookline Capital Markets also issued estimates for CRISPR Therapeutics’ Q4 2026 earnings at ($1.17) EPS and FY2027 earnings at ($3.83) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, November 2nd. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.09). The company had revenue of $12.67 million for the quarter, compared to analyst estimates of $14.75 million. CRISPR Therapeutics had a negative net margin of 1,812.07% and a negative return on equity of 25.59%. The company’s revenue was up 1311.1% on a year-over-year basis.

A number of other analysts have also recently commented on the company. Citizens Jmp reiterated a “market outperform” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, August 31st. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $55.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. William Blair upgraded CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Wells Fargo & Company reduced their price target on CRISPR Therapeutics from $75.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of CRISPR Therapeutics in a research report on Friday, October 9th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $69.69.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $51.78 on Thursday. The company has a quick ratio of 17.85, a current ratio of 16.21 and a debt-to-equity ratio of 0.36. CRISPR Therapeutics has a fifty-two week low of $44.12 and a fifty-two week high of $63.45. The business has a fifty day moving average of $53.67 and a 200-day moving average of $52.84. The stock has a market cap of $5.01 billion, a price-to-earnings ratio of -10.92 and a beta of 1.92.

Insider Activity at CRISPR Therapeutics

In related news, General Counsel James Kasinger sold 10,400 shares of CRISPR Therapeutics stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $60.24, for a total value of $626,496.00. Following the transaction, the general counsel owned 94,784 shares in the company, valued at approximately $5,709,788.16. This trade represents a 9.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ali Behbahani sold 13,679 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $57.09, for a total value of $780,934.11. Following the sale, the director directly owned 16,637 shares of the company’s stock, valued at approximately $949,806.33. This trade represents a 45.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 93,558 shares of company stock worth $4,881,663 in the last 90 days. Company insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Choreo LLC increased its position in CRISPR Therapeutics by 3.4% during the 3rd quarter. Choreo LLC now owns 7,539 shares of the company’s stock worth $417,000 after purchasing an additional 247 shares in the last quarter. Sterling Capital Management LLC grew its stake in CRISPR Therapeutics by 15.5% during the third quarter. Sterling Capital Management LLC now owns 1,934 shares of the company’s stock worth $107,000 after buying an additional 260 shares during the period. Interchange Capital Partners LLC grew its stake in CRISPR Therapeutics by 6.0% during the third quarter. Interchange Capital Partners LLC now owns 4,766 shares of the company’s stock worth $264,000 after buying an additional 268 shares during the period. Versant Capital Management Inc grew its stake in CRISPR Therapeutics by 175.1% during the second quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after buying an additional 296 shares during the period. Finally, Sunbelt Securities Inc. raised its stake in shares of CRISPR Therapeutics by 4.5% in the 1st quarter. Sunbelt Securities Inc. now owns 7,843 shares of the company’s stock valued at $373,000 after acquiring an additional 336 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Citigroup raised its price target to $90 from $88 and reaffirmed a “buy” rating, signaling significant potential upside in the analyst’s view. Citigroup price target report
• Positive Sentiment: The company said it will present Phase 1/2 clinical data for zugo-cel, its investigational gene-edited CAR T therapy for relapsed or refractory large B-cell lymphoma, at the ASH meeting in December. The presentation could provide investors with a meaningful pipeline update. Zugo-cel clinical data announcement
• Neutral Sentiment: CRISPR Therapeutics appointed Siva Sakhamuri as chief technical officer. His experience in manufacturing, gene editing and commercial launches may support the company’s operations, though the appointment’s financial impact is not yet clear. Chief technical officer appointment
• Negative Sentiment: Third-quarter results fell short of expectations: the company reported a $1.15-per-share loss versus the $1.06 loss analysts expected, and revenue of $12.67 million versus a $14.75 million consensus estimate. Growing Casgevy use and sales offer a counterpoint, but the earnings shortfall may weigh on sentiment. Third-quarter results coverage
• Negative Sentiment: Brookline Capital Markets slightly lowered its projected earnings per share for 2028, 2029 and 2030, a modestly cautious revision to its long-term outlook.

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.